2007.08.20 -DNDN

Pre-market:

NASDAQ:DNDN - +10% gap a pre-marketben...

"Dendreon Says Breast Cancer Investigational Drug Phase 1 Study Results Promising - Quick Facts

(RTTNews) - Dendreon Corp. (DNDN) on Friday said a Phase 1 study of NEUVENGE, an investigational active cellular immunotherapy to be used in women with HER2/neu-positive breast cancer who have failed standard therapy, said results showed the drug was safe and well tolerated. The results added that the T-cell responses seen in these patients and the prolonged disease stabilization in the absence of other anti-cancer therapies in many patients is promising."

Market open:

Kezdés után lefelé indult - nem nyerő...

Ezzel a charttal nem sokat lehet kezdeni...

Market closed